09 September 2024
The Fms-like tyrosine kinase 3 (FLT3) receptor is expressed by bone marrow progenitors at different stages of lymphoid and myeloid development. When the natural ligand binds to the FLT3 receptor, it triggers receptor dimerization and activates the downstream STAT3/STAT5 signaling pathway. This activation stimulates the growth of hematopoietic progenitors, promotes lymphoid lineage commitment, and drives dendritic cell development. We offer a highly potent and selective humanized antibody, BI-3404, for FLT3 receptor research. This antibody mimics the natural FLT3 ligand and may serve as an effective tool for investigating the role of FLT3 activation in various diseases.
To have a chance to access BI-3404 and get funded, we invite scientists from all over the world to submit testable research proposals to the following question:
How would you propose to demonstrate the utility of our FLT3 agonist BI-3404 in novel disease indications?
Should your research proposal be selected as a winner, you will be able to obtain the FLT3 agonist BI-3404 in the amounts required for in vitro and in vivo experiments to validate your hypotheses. You will also directly interact with Boehringer Ingelheim scientists and benefit from access to their expertise. Add a funding request to your proposal, as winning scientists should expect funding of up to 250,000 euros for a fruitful research collaboration.
Submit your ideas now, as your proposal can only be accepted if they arrive by November 12, 2024, 11:59 pm PST.
No registration required for download
Subscribe to our newsletter to stay updated as we add new calls for proposals to opnMe.com
About our call for “Molecules for Collaboration”:
On opnMe, we now offer BI-3404, a potent and highly selective humanized antibody activating the FLT3 receptor by mimicking its natural ligand. BI-3404 can be used in vitro as well as in vivo. Demonstrate the utility of FLT3 activation in novel disease indications for a chance to access our antibody and get funded. Submit your proposals through November 12, 2024. Learn more…
About opnMe:
opnMe.com, the open science portal of Boehringer Ingelheim, fosters science and collaboration initiatives in areas of high unmet medical need. Our molecules are provided to the scientific community either free of charge as “Molecules to Order” or applied for via scientific research submissions as “Molecules for Collaboration”. With our “opn2EXPERTS” and “techMATCH” programs, we enlist scientific advice on key scientific topics to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs. Our "opn2TALENTS" postdoc grants at one of our research sites offer opportunities for high-level talents to propose innovative approaches for precisely defined scientific questions.